France’s Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But the CEO says he’s laying the groundwork for a late-stage study, confident that he can find another partner.

…read more

Source: Transgene takes a hit as Novartis shreds $800M option deal


0 No comments